The Lancet Diabetes & Endocrinology
IF
25.34
Papers
1577
Papers 1797
1 page of 180 pages (1,797 results)
Newest
#1Hiddo J.L. Heerspink (The George Institute for Global Health)H-Index: 70
#2Niels Jongs (UMCG: University Medical Center Groningen)H-Index: 3
Last. Robert D. Toto (UTSW: University of Texas Southwestern Medical Center)H-Index: 58
view all 14 authors...
Background null Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change in estimated glomerular filtration rate (eGFR)-ie, the eGFR slope. null Methods null DAPA-CKD was a randomised controlled trial that enrolled participants aged 18 years or older, with or without type 2 diabetes, with a urinary albumin-to-creatin...
2 CitationsSource
#1Charlotte Steenblock (TUD: Dresden University of Technology)H-Index: 10
#2Peter Schwarz (TUD: Dresden University of Technology)H-Index: 63
Last. Martin Hrabě de Angelis (TUM: Technische Universität München)H-Index: 42
view all 36 authors...
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Revi...
Source
Summary null null Background null Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal or near-normal kidney function. Whether this effect persists in patients with chronic kidney disease with and without type 2 diabetes is unknown. We assessed the effects of dapagliflozin on albuminuria in patients with chroni...
2 CitationsSource
Source
#1Nicole A.J. Krentz (Stanford University)H-Index: 7
#2Lonnie D. Shea (UM: University of Michigan)H-Index: 81
Last. James Shaw (Newcastle University)H-Index: 30
view all 4 authors...
Summary null null Type 1 diabetes is characterised by autoimmune-mediated destruction of pancreatic β-cell mass. With the advent of insulin therapy a century ago, type 1 diabetes changed from a progressive, fatal disease to one that requires lifelong complex self-management. Replacing the lost β-cell mass through transplantation has proven successful, but limited donor supply and need for lifelong immunosuppression restricts widespread use. In this Review, we highlight incremental advances over ...
2 CitationsSource
#1Christel Jm de Blok (UvA: University of Amsterdam)
#2Chantal M. Wiepjes (UvA: University of Amsterdam)H-Index: 3
Last. Martin den Heijer (UvA: University of Amsterdam)H-Index: 6
view all 8 authors...
Summary null null Background null Increased mortality in transgender people has been described in earlier studies. Whether this increased mortality is still present over the past decades is unknown. Therefore, we aimed to investigate trends in mortality over five decades in a large cohort of adult transgender people in addition to cause-specific mortality. null null null Methods null We did a retrospective cohort study of adult transgender people who visited the gender identity clinic of Amsterd...
2 CitationsSource
#1Bart Van der Schueren (Katholieke Universiteit Leuven)H-Index: 20
#2Darcy Ellis (Katholieke Universiteit Leuven)
Last. Chantal Mathieu (Katholieke Universiteit Leuven)H-Index: 113
view all 6 authors...
Summary null Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Non-physiological insulin replacement that causes peripheral hyperinsulinaemia, insulin profiles that do not match basal and mealtime insulin needs, defensive snacking to avoid hypoglycaemia, or a combination of these, are believed to affect body composition and drive excessive accumulation of body fat in peo...
Source
#1Giulia Lanzolla (UniPi: University of Pisa)H-Index: 6
#2Elena Sabini (UniPi: University of Pisa)H-Index: 7
Last. Michele Marinò (UniPi: University of Pisa)H-Index: 35
view all 10 authors...
Summary null null Background null A protective action of statins on development of Graves' orbitopathy suggests that statins might be used for treatment of the disease. We aimed to assess the efficacy of the addition of a statin, atorvastatin, to intravenous glucocorticoids (ivGCs) on Graves' orbitopathy outcomes in patients with hypercholesterolaemia. null null null Methods null We did a randomised, open-label, phase 2, adaptive, clinical trial at a single, tertiary, referral hospital in Pisa, ...
Source
#1Luigi Bartalena (University of Insubria)H-Index: 73
#2Eliana Piantanida (University of Insubria)H-Index: 21
Last. Maria Laura Tanda (University of Insubria)H-Index: 29
view all 3 authors...
Source
#1Claire Burgess (Harvard University)H-Index: 1
#2Abagail W Batchelder (Harvard University)
Last. Carl G. Streed (BU: Boston University)H-Index: 11
view all 5 authors...
Source
12345678910
Top fields of study
Internal medicine
Endocrinology
Type 2 diabetes
MEDLINE
Population
Diabetes mellitus
Medicine